A carregar...

Real-world utilization patterns and outcomes of colesevelam hcl in the ge electronic medical record

BACKGROUND: In randomized controlled trials (RCTs), colesevelam HCI, added to other anti-diabetic therapy, reduced hemoglobin A1C by approximately 0.3% to 0.4% over 16- to 26-weeks compared with an increase of approximately 0.1% to 0.2% for placebo, for a placebo-adjusted treatment effect of approxi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hansen, Richard A, Farley, Joel F, Maciejewski, Matthew L, Ye, Xin, Qian, Chunlin, Powers, Ben
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2013
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3750408/
https://ncbi.nlm.nih.gov/pubmed/23866087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1472-6823-13-24
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!